AU2001273574A1 - Substituted 5-alkynyl pyrimidines having neurotrophic activity - Google Patents
Substituted 5-alkynyl pyrimidines having neurotrophic activityInfo
- Publication number
- AU2001273574A1 AU2001273574A1 AU2001273574A AU7357401A AU2001273574A1 AU 2001273574 A1 AU2001273574 A1 AU 2001273574A1 AU 2001273574 A AU2001273574 A AU 2001273574A AU 7357401 A AU7357401 A AU 7357401A AU 2001273574 A1 AU2001273574 A1 AU 2001273574A1
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- neurotrophic activity
- pyrimidines
- alkynyl
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000508 neurotrophic effect Effects 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22034800P | 2000-07-24 | 2000-07-24 | |
| US60220348 | 2000-07-24 | ||
| PCT/US2001/023088 WO2002008205A1 (en) | 2000-07-24 | 2001-07-20 | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001273574A1 true AU2001273574A1 (en) | 2002-02-05 |
Family
ID=22823191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001273574A Abandoned AU2001273574A1 (en) | 2000-07-24 | 2001-07-20 | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7205297B2 (da) |
| EP (1) | EP1303495B1 (da) |
| JP (2) | JP5154728B2 (da) |
| AT (1) | ATE469132T1 (da) |
| AU (1) | AU2001273574A1 (da) |
| CA (1) | CA2416442C (da) |
| DE (1) | DE60142236D1 (da) |
| DK (1) | DK1303495T3 (da) |
| ES (1) | ES2346513T3 (da) |
| WO (1) | WO2002008205A1 (da) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003094830A2 (en) * | 2002-05-07 | 2003-11-20 | Neurosearch A/S | Novel azacyclic ethynyl derivatives |
| US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
| UA80888C2 (en) | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| ES2358512T3 (es) * | 2003-06-12 | 2011-05-11 | F. Hoffmann-La Roche Ag | Derivados de imidazol, sustituidos por heteroarilo como antagonistas del receptor de glutamato. |
| WO2005016914A1 (en) * | 2003-08-14 | 2005-02-24 | Smithkline Beecham Corporation | Chemical compounds |
| DE602004015509D1 (de) * | 2003-12-24 | 2008-09-11 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
| DE602004018193D1 (de) * | 2003-12-24 | 2009-01-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
| NZ551253A (en) | 2004-06-01 | 2010-07-30 | Hoffmann La Roche | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| CA2587427A1 (en) * | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| JP2008528663A (ja) * | 2005-02-01 | 2008-07-31 | アストラゼネカ アクチボラグ | Ｔｉｅｓ（ＴＥＫ）阻害活性を有するピリミジン化合物 |
| JP4993205B2 (ja) * | 2005-03-30 | 2012-08-08 | 塩野義製薬株式会社 | チロシンキナーゼ阻害作用を有するピリミジン誘導体 |
| ES2535854T3 (es) * | 2005-09-30 | 2015-05-18 | Miikana Therapeutics, Inc. | Compuestos de pirazol sustituidos |
| ES2699585T3 (es) | 2006-12-15 | 2019-02-11 | Nantbio Inc | Derivados de triazina y sus aplicaciones terapéuticas |
| NZ577440A (en) | 2006-12-21 | 2011-12-22 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| US20090029992A1 (en) * | 2007-06-11 | 2009-01-29 | Agoston Gregory E | Substituted pyrazole compounds |
| CN104975020B (zh) | 2008-02-11 | 2020-01-17 | 菲奥医药公司 | 经修饰的RNAi多核苷酸及其用途 |
| WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
| EA201100255A1 (ru) * | 2008-07-29 | 2011-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 5-алкинилпиримидины |
| AR072940A1 (es) * | 2008-08-20 | 2010-09-29 | Schering Corp | Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales |
| CA2734489C (en) | 2008-08-20 | 2016-11-08 | Southern Research Institute | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| EP2326627A1 (en) | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| JP6209309B2 (ja) | 2008-09-22 | 2017-10-04 | アールエックスアイ ファーマシューティカルズ コーポレーション | サイズが減少した自己送達用ＲＮＡｉ化合物 |
| US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| BRPI1011318A2 (pt) | 2009-06-09 | 2019-09-24 | California Capital Equity Llc | derivados de triazina e suas aplicações terapêuticas |
| CA2765044A1 (en) | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| WO2011053701A1 (en) * | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| UY33199A (es) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
| EP3578183B1 (en) | 2010-03-24 | 2021-09-08 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
| UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| US10934550B2 (en) | 2013-12-02 | 2021-03-02 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer |
| WO2015085113A1 (en) | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| US20170051290A1 (en) | 2014-05-01 | 2017-02-23 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
| CN107073294A (zh) | 2014-09-05 | 2017-08-18 | 阿克赛医药公司 | 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法 |
| WO2017007825A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| EP3319614B1 (en) | 2015-07-06 | 2020-12-23 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
| CA3002744A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| US20230002766A1 (en) | 2019-11-08 | 2023-01-05 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy |
| EP4085136A1 (en) | 2019-12-31 | 2022-11-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
| WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
| KR20240041973A (ko) | 2021-08-04 | 2024-04-01 | 피오 파마슈티칼스 코프. | 화학적으로 변형된 올리고뉴클레오티드 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691655A (en) * | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
| GB951431A (en) * | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
| US3862190A (en) * | 1972-09-08 | 1975-01-21 | Pfizer | 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines |
| DK397574A (da) * | 1973-08-24 | 1975-04-28 | Ciba Geigy Ag | |
| GB1523274A (en) | 1974-08-05 | 1978-08-31 | Ici Ltd | Herbicidal compositions containing substituted pyrimidine |
| FR2358148A1 (fr) | 1976-07-12 | 1978-02-10 | Dick Pr | Derives de 2,4-diaminopyrimidines et leur mise en solution en association avec des sulfamides |
| FR2397407A2 (fr) | 1977-07-11 | 1979-02-09 | Dick Pierre | Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides |
| US4508560A (en) * | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
| US4663334A (en) * | 1985-12-11 | 1987-05-05 | Mcneilab, Inc. | Heteroaromatic acetylenes useful as antihypertensive agents |
| FI895821A0 (fi) * | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
| GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| IE912114A1 (en) | 1990-07-02 | 1992-01-15 | Union Pharma Scient Appl | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present |
| US5075305A (en) * | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
| US5250532A (en) | 1991-04-11 | 1993-10-05 | Dowelanco | 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides |
| JPH0819121B2 (ja) | 1991-04-17 | 1996-02-28 | フアイザー・インコーポレイテツド | 抗腫瘍活性を増強するためのピリミジン誘導体 |
| US5336677A (en) | 1991-10-24 | 1994-08-09 | American Home Products Corporation | Substituted aminopyrimidines as antihypertensives |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| JPH08504798A (ja) * | 1992-12-18 | 1996-05-21 | ザ ウエルカム ファウンデーション リミテッド | 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体 |
| US5719303A (en) | 1993-03-08 | 1998-02-17 | Eisai Co., Ltd. | Phosphonic acid derivatives |
| DK0640599T3 (da) * | 1993-08-26 | 1998-09-28 | Ono Pharmaceutical Co | 4-Aminopyrimidin-derivater |
| JPH08283246A (ja) | 1994-06-01 | 1996-10-29 | Nippon Soda Co Ltd | ピリミジン誘導体、その製造方法及び有害生物防除剤 |
| CA2217034A1 (en) | 1995-04-03 | 1996-10-10 | Sumitomo Pharmaceuticals Company, Limited | Novel pyrimidine derivatives effective as psychotropic drug and process for the production thereof |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6583148B1 (en) * | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
-
2001
- 2001-07-20 ES ES01952859T patent/ES2346513T3/es not_active Expired - Lifetime
- 2001-07-20 CA CA2416442A patent/CA2416442C/en not_active Expired - Fee Related
- 2001-07-20 AU AU2001273574A patent/AU2001273574A1/en not_active Abandoned
- 2001-07-20 DE DE60142236T patent/DE60142236D1/de not_active Expired - Lifetime
- 2001-07-20 WO PCT/US2001/023088 patent/WO2002008205A1/en active Application Filing
- 2001-07-20 DK DK01952859.5T patent/DK1303495T3/da active
- 2001-07-20 AT AT01952859T patent/ATE469132T1/de not_active IP Right Cessation
- 2001-07-20 EP EP01952859A patent/EP1303495B1/en not_active Expired - Lifetime
- 2001-07-20 JP JP2002514111A patent/JP5154728B2/ja not_active Expired - Lifetime
- 2001-07-20 US US10/333,447 patent/US7205297B2/en not_active Expired - Lifetime
-
2012
- 2012-06-11 JP JP2012132101A patent/JP2012229218A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1303495A1 (en) | 2003-04-23 |
| WO2002008205A1 (en) | 2002-01-31 |
| CA2416442A1 (en) | 2002-01-31 |
| EP1303495B1 (en) | 2010-05-26 |
| ATE469132T1 (de) | 2010-06-15 |
| DK1303495T3 (da) | 2010-09-20 |
| JP2004504386A (ja) | 2004-02-12 |
| CA2416442C (en) | 2010-06-08 |
| US7205297B2 (en) | 2007-04-17 |
| US20040087789A1 (en) | 2004-05-06 |
| ES2346513T3 (es) | 2010-10-18 |
| JP2012229218A (ja) | 2012-11-22 |
| JP5154728B2 (ja) | 2013-02-27 |
| DE60142236D1 (de) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001273574A1 (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
| AU4331400A (en) | Neurotrophic substituted pyrimidines | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| WO2003002596A3 (en) | Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders | |
| WO2003092580A3 (en) | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | |
| IL118836A0 (en) | Pharmaceutical compositions comprising S-(-)N-propargyl-1-aminoindan | |
| IL147271A0 (en) | Compounds that bind her2 | |
| EA200200183A1 (ru) | Композиция, содержащая трамадол и противосудорожное лекарственное средство | |
| TW200500344A (en) | Novel compounds | |
| BG104686A (en) | Glycine transport inhibitors | |
| MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
| SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
| MY124786A (en) | Bis-arylsulfones | |
| DK0884316T3 (da) | Quinazolin-4-on AMPA-antagonister | |
| MX2007007472A (es) | Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c. | |
| EP1032556A4 (en) | PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION | |
| PT1463735E (pt) | Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas | |
| EP1736470A3 (en) | Pyrimidine derivatives as CB2 cannabinoid receptor modulators | |
| BR9803385A (pt) | AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas. | |
| AP9901473A0 (en) | Use of benzopyranols to treat neurological disorders. | |
| IL143382A0 (en) | Human adult astrocytes, their preparation and uses thereof | |
| IL136306A (en) | Bis (fluorophenyl) alkylamides and related compounds, pharmaceutical compositions comprising them and their use in treating neurological disease or disorder | |
| WO2001082954A3 (en) | Ceruloplasmin and uses thereof in neurodegenerative related conditions |